Oral contraception affects osteocalcin serum profiles in young women

Osteoporos Int. 1992 May;2(3):118-21. doi: 10.1007/BF01623817.

Abstract

The serum concentrations of osteocalcin (bone Gla protein) were followed by continuous blood sampling for 24 h in 9 healthy young women before and during treatment with oestrogen/progestogen combinations for oral contraception. There were marked fluctuations during the 24 h sampling period, values ranging from 0.5 to 10.0 ng/ml. Values displayed an apparent circadian rhythm. Daytime values were on average lower than nocturnal concentrations. During treatment with oral contraceptives there was a significant decrease in osteocalcin levels but fluctuations during the 24 h sampling period were still observed. Almost all individual values obtained at 30 min intervals were lower during treatment. For the whole group the mean osteocalcin concentration decreased by 1.4 ng/ml (p less than 0.01) during treatment. In postmenopausal women high serum levels of osteocalcin are supposed to reflect increased bone turnover secondary to enhanced bone resorption. Oestrogens are known to reduce osteocalcin levels and may reduce bone resorption. In healthy young women alternative mechanisms should be considered but the reduced osteocalcin serum levels in this short-term study indicate that oral contraceptive use may influence bone metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Circadian Rhythm
  • Contraceptives, Oral / pharmacology*
  • Desogestrel
  • Ethinyl Estradiol / pharmacology
  • Female
  • Humans
  • Norpregnenes / pharmacology
  • Osmolar Concentration
  • Osteocalcin / blood*

Substances

  • Contraceptives, Oral
  • Norpregnenes
  • Osteocalcin
  • Ethinyl Estradiol
  • Desogestrel